InstalabLoading...
InstalabLoading...
Most people think of bile acids as digestive juice, but they are also messengers. They tell your gut bacteria what to do, regulate inflammation, and influence how your body handles sugar and fat. When the balance shifts, especially when taurocholic acid (TCA) builds up in the gut, it can signal that something deeper is changing in your liver, microbiome, or metabolism.
This test measures TCA in a stool sample, giving a window into what is actually reaching and lingering in your gut rather than what is circulating in your blood. It is an emerging research-grade marker, not a standardized clinical test, but it can offer early insight into patterns linked to inflammatory bowel disease, fatty liver, and gut microbiome disruption that routine blood work will not catch.
Your liver builds TCA by attaching the amino acid taurine to cholic acid, a primary bile acid. The conjugated molecule is more water-soluble, which lets it dissolve dietary fat in the small intestine. After it has done its digestive job, most of it gets pulled back into the bloodstream from the lower small intestine and recycled back to the liver, a loop scientists call enterohepatic circulation.
Some TCA escapes that recycling and reaches the colon, where it interacts with gut bacteria, hormone-producing cells, and bile acid receptors. The amount that ends up in your stool reflects the balance between how much your liver is making, how efficiently your small intestine is reabsorbing it, and how your gut microbes are processing it once it arrives.
The most direct stool-based evidence ties elevated fecal TCA to inflammatory bowel disease (IBD). In a study of 55 people with ulcerative colitis, higher fecal TCA and the related taurine-conjugated bile acid taurochenodeoxycholate tracked with greater inflammation and altered bile acid receptor activity in the colon. The pattern reflects both impaired reabsorption in the lower small intestine and a microbiome that has shifted toward bacteria that thrive on sulfur-rich substrates.
Reviews of the fecal sulfur chemistry in IBD consistently find elevated taurine-conjugated bile acids alongside increased hydrogen sulfide-producing bacteria. This combination can feed a cycle where inflammation alters bile acid handling, the changed bile acids favor pro-inflammatory microbes, and those microbes produce compounds that further irritate the gut lining.
The bulk of evidence linking TCA to liver disease comes from serum measurements rather than stool, which is a related but different reading. Studies measuring serum TCA (a different specimen than this test) have repeatedly found it elevated in non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD), and progressive fibrosis. In a community-based study of 2,672 middle-aged and older adults, higher serum TCA was associated with NAFLD development.
A prospective study of 600 adults found that people with the highest baseline serum conjugated bile acids, including TCA, had roughly 5 to 7 times the odds of developing liver cancer or fatal liver disease compared to those with the lowest levels. Whether stool TCA tracks the same risk in the same way has not been directly established, but the underlying biology of bile acid disturbance is shared.
A pilot study of 22 people with age-related macular degeneration (AMD) found lower fecal TCA in advanced AMD compared to controls, as part of a broader loss of bile acids and shifts in short-chain fatty acid producers. The finding is preliminary and based on a small sample, but it points to the principle that fecal TCA can move in either direction depending on the underlying disturbance, and that very low values are not automatically reassuring.
In a large study of normoglycemic Chinese adults, those with the highest baseline serum conjugated primary bile acids, including TCA, had a higher risk of developing type 2 diabetes over about three years, even after adjusting for liver enzymes, insulin resistance, body weight, and lifestyle. This was a serum measurement, not stool. Still, it suggests that the conjugated bile acid pool is part of a broader metabolic signal rather than a purely digestive one.
It is tempting to read TCA as a simple good number versus bad number marker, but the evidence does not support that. Both higher fecal TCA (in inflammatory bowel disease) and lower fecal TCA (in advanced macular degeneration) have been linked to disease in different contexts. TCA is better thought of as a phenotype indicator: the level itself only becomes meaningful when paired with other markers of gut inflammation, microbial composition, and liver function. A reading outside the typical range is a prompt to investigate, not a diagnosis.
There are no universally accepted clinical cutpoints for stool TCA. Published values come from research cohorts and vary widely by lab, assay method, and population. The framework below is illustrative orientation drawn from the patterns reported in inflammatory bowel disease and gut microbiome studies, not a universal target. Your lab will likely report different numbers, possibly in different units. Compare your results within the same lab over time for the most meaningful trend.
| Pattern | What It Suggests |
|---|---|
| Within typical research-reported range | Bile acid handling and gut microbial processing appear balanced. Useful as a baseline for future trending. |
| Elevated | May reflect impaired reabsorption in the lower small intestine, altered gut microbes, or inflammatory bowel disease pattern. Worth pairing with calprotectin and a bile acid panel. |
| Markedly low | Has been seen in advanced age-related macular degeneration and broader bile acid loss. Worth checking pancreatic and overall bile acid output. |
A single TCA measurement is a snapshot. Stool composition shifts with diet, medications, gut transit time, and microbial activity, so any one reading carries meaningful day-to-day variability. The stronger signal comes from the trajectory: a value that climbs steadily over months while you also notice digestive symptoms is a different story than a single elevated number in a stable, asymptomatic person.
Get a baseline, retest in 3 to 6 months if you are making targeted changes (diet, probiotics, treatment for inflammation), then at least annually thereafter. Trending matters more than the absolute number, and pairing your TCA trend with markers of gut inflammation and overall bile acid composition will tell you more than TCA alone.
An out-of-range TCA result on its own does not warrant a diagnosis. The useful next step is to pair it with companion markers: calprotectin to assess gut inflammation, pancreatic elastase to check digestive function, and a full stool bile acid panel to see whether the imbalance is isolated to TCA or part of a broader pattern. If you also have liver risk factors, basic liver enzymes and an imaging-based fibrosis assessment add context.
If your TCA is elevated alongside high calprotectin or persistent gastrointestinal symptoms, that pattern is worth investigating with a gastroenterologist. If it is elevated in the context of fatty liver risk, a hepatologist or a clinician familiar with metabolic liver disease can help interpret the finding alongside imaging and serum markers. For a clean baseline result with no symptoms, the action is to track.
Several factors can distort a single stool TCA reading and lead to the wrong conclusion:
Evidence-backed interventions that affect your Taurocholic Acid level
Taurocholic Acid is best interpreted alongside these tests.